Engineered antibody fragments and the rise of single domains
P Holliger, PJ Hudson - Nature biotechnology, 2005 - nature.com
With 18 monoclonal antibody (mAb) products currently on the market and more than 100 in
clinical trials, it is clear that engineered antibodies have come of age as biopharmaceuticals …
clinical trials, it is clear that engineered antibodies have come of age as biopharmaceuticals …
Engineered antibody fragments and the rise of single domains.
P Holliger, PJ Hudson - Nature Biotechnology, 2005 - europepmc.org
With 18 monoclonal antibody (mAb) products currently on the market and more than 100 in
clinical trials, it is clear that engineered antibodies have come of age as biopharmaceuticals …
clinical trials, it is clear that engineered antibodies have come of age as biopharmaceuticals …
[引用][C] Engineered antibody fragments and the rise of single domains
P Holliger, PJ Hudson - Nature Biotechnology, 2005 - cir.nii.ac.jp
[引用][C] Engineered antibody fragments and the rise of single domains: Antibody engineering and manufacture
P HOLLIGER, PJ HUDSON - Nature biotechnology, 2005 - pascal-francis.inist.fr
Engineered antibody fragments and the rise of single domains : Antibody engineering and
manufacture CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases …
manufacture CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases …
[PDF][PDF] Engineered antibody fragments and the rise of single domains
P Holliger, PJ Hudson - NATURE …, 2005 - oww-files-public.s3.amazonaws.com
With 18 monoclonal antibody (mAb) products currently on the market and more than 100 in
clinical trials, it is clear that engineered antibodies have come of age as biopharmaceuticals …
clinical trials, it is clear that engineered antibodies have come of age as biopharmaceuticals …
Engineered antibody fragments and the rise of single domains
P Holliger, PJ Hudson - Nature biotechnology, 2005 - pubmed.ncbi.nlm.nih.gov
With 18 monoclonal antibody (mAb) products currently on the market and more than 100 in
clinical trials, it is clear that engineered antibodies have come of age as biopharmaceuticals …
clinical trials, it is clear that engineered antibodies have come of age as biopharmaceuticals …
[PDF][PDF] Engineered antibody fragments and the rise of single domains
P Holliger, PJ Hudson - NATURE BIOTECHNOLOGY, 2005 - researchgate.net
With 18 monoclonal antibody (mAb) products currently on the market and more than 100 in
clinical trials, it is clear that engineered antibodies have come of age as biopharmaceuticals …
clinical trials, it is clear that engineered antibodies have come of age as biopharmaceuticals …
Engineered antibody fragments and the rise of single domains
P Holliger, PJ Hudson - Nature Biotechnology, 2005 - go.gale.com
With 18 monoclonal antibody (mAb) products currently on the market and more than 100 in
clinical trials, it is clear that engineered antibodies have come of age as biopharmaceuticals …
clinical trials, it is clear that engineered antibodies have come of age as biopharmaceuticals …
Engineered antibody fragments and the rise of single domains.
P Holliger, PJ Hudson - Nature Biotechnology, 2005 - search.ebscohost.com
With 18 monoclonal antibody (mAb) products currently on the market and more than 100 in
clinical trials, it is clear that engineered antibodies have come of age as biopharmaceuticals …
clinical trials, it is clear that engineered antibodies have come of age as biopharmaceuticals …
[引用][C] Engineered antibody fragments and the rise of single domains
P Holliger - (No Title), 2005 - cir.nii.ac.jp
Engineered antibody fragments and the rise of single domains | CiNii Research CiNii 国立
情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす …
情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす …